Advertisement

Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment

  • André Mansinho
  • Daniela Macedo
  • Isabel Fernandes
  • Luís Costa
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1126)

Abstract

Prostate cancer is the most common malignancy in men, and remains the second leading cause of cancer-related death in this gender [1]. Data suggests that 10–20% of patients with prostate cancer metastasis develop castration-resistant prostate cancer (CRPC) within 5 years of follow-up, and that the median survival since development of castration resistance is approximately 14 months (range 9–30) [2]. Additionally, patients with non-metastatic CRPC are at higher risk of disease progression. Approximately 15–33% of patients develop metastasis within 2 years, increasing the mortality burden in this population [3, 4].

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29. https://doi.org/10.3322/caac.21254 pmid:25559415CrossRefGoogle Scholar
  2. 2.
    Kirby M, Hirst C, Crawford ED (2011) Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 65:1180–1192. https://doi.org/10.1111/j.1742-1241.2011.02799.x pmid:21995694CrossRefPubMedGoogle Scholar
  3. 3.
    Hirst CJ, Cabrera C, Kirby M (2012) Epidemiology of castration resistant prostate cancer: a longitudinal analysis using a UK primary care database. Cancer Epidemiol 36:e349–e353. https://doi.org/10.1016/j.canep.2012.07.012 pmid:22910034CrossRefPubMedGoogle Scholar
  4. 4.
    Smith MR, Kabbinavar F, Saad F et al (2005) Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23:2918–2925. https://doi.org/10.1200/JCO.2005.01.529 pmid:15860850CrossRefPubMedGoogle Scholar
  5. 5.
    Tannock IF, de Wit R, Berry WR et al (2004) TAX 327 investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512. https://doi.org/10.1056/NEJMoa040720 pmid:15470213CrossRefGoogle Scholar
  6. 6.
    Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520. https://doi.org/10.1056/NEJMoa041318 pmid:15470214CrossRefPubMedGoogle Scholar
  7. 7.
    Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G (2015) Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol 16:e279–e292. https://doi.org/10.1016/S1470-2045(15)70033-1 pmid:26065613CrossRefPubMedGoogle Scholar
  8. 8.
    Antonarakis ES, Lu C, Wang H et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028–1038. https://doi.org/10.1056/NEJMoa1315815 pmid:25184630CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Karantanos T, Corn PG, Thompson TC (2013) Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32:5501–5511. https://doi.org/10.1038/onc.2013.206 pmid:23752182CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Harris WP, Mostaghel EA, Nelson PS, Montgomery B (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6:76–85. https://doi.org/10.1038/ncpuro1296 pmid:19198621CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Marques RB, Dits NF, Erkens-Schulze S, van Weerden WM, Jenster G (2010) Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS One 5:e13500. https://doi.org/10.1371/journal.pone.0013500 pmid:20976069CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Stein M et al (2014) Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl 16:387–400CrossRefGoogle Scholar
  13. 13.
    de Bono JS, Logothetis CJ, Molina A et al (2011) COU-AA-301 investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005. https://doi.org/10.1056/NEJMoa1014618 pmid:21612468CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Fizazi K, Scher HI, Molina A et al (2012) COU-AA-301 investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983–992. https://doi.org/10.1016/S1470-2045(12)70379-0 pmid:22995653CrossRefPubMedGoogle Scholar
  15. 15.
    Scher HI, Fizazi K, Saad F et al (2012) AFFIRM investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197. https://doi.org/10.1056/NEJMoa1207506 pmid:22894553CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Ryan CJ, Smith MR, Fizazi K et al (2014) Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer. Ann Oncol 25(Sppl 4):iv255–iv279CrossRefGoogle Scholar
  17. 17.
    Beer TM, Armstrong AJ, Rathkopf DE et al (2014) PREVAIL investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433. https://doi.org/10.1056/NEJMoa1405095 pmid:24881730CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G (2015) Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol 16:e279–e292CrossRefGoogle Scholar
  19. 19.
    Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520CrossRefGoogle Scholar
  20. 20.
    Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisolone ou mitoxantrone plus prednisolone for advanced prostate cancer. N Engl J Med 351:1502–1512CrossRefGoogle Scholar
  21. 21.
    Pond G et al (2012) Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol 61(2):363–369CrossRefGoogle Scholar
  22. 22.
    Kume H et al (2015) Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer. Mol Clin Oncol 3:303–307CrossRefGoogle Scholar
  23. 23.
    Beer T et al (2003) Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer. Br J Cancer 89(6):968–970CrossRefGoogle Scholar
  24. 24.
    Oudard S et al (2015) Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. BJU Int 115(5):744–752CrossRefGoogle Scholar
  25. 25.
    Kellokumpu-Lehtinen PL et al (2013) 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 14(2):117–124CrossRefGoogle Scholar
  26. 26.
    Vrignaud P, Semiond D, Lejeune P et al (2013) Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in axaneresistant tumors. Clin Cancer Res 19:2973–2983CrossRefGoogle Scholar
  27. 27.
    Oudard S, Fizazi K, Sengeløv L et al (2017) Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol 35(28):3189–3197CrossRefGoogle Scholar
  28. 28.
    Eisenberger M, Hardy-Bessard AC, Kim CS et al (2017) Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol 35(28):3198–3206CrossRefGoogle Scholar
  29. 29.
    de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 376:1147–1154CrossRefGoogle Scholar
  30. 30.
    Kantoff P et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422CrossRefGoogle Scholar
  31. 31.
    Parker C, Nilsson S, Heinrich D et al (2013) ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223. https://doi.org/10.1056/NEJMoa1213755 pmid:23863050CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Hoskin P, Sartor O, O’Sullivan JM et al (2014) Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 15:1397–1406. https://doi.org/10.1016/S1470-2045(14)70474-7 pmid:25439694CrossRefPubMedGoogle Scholar
  33. 33.
    Antonarakis ES, Lu C, Wang H et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11):1028–1038CrossRefGoogle Scholar
  34. 34.
    Antonarakis ES, Lu C, Luber B et al (2015) Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 1(5):582–591CrossRefGoogle Scholar
  35. 35.
    Scher H, Graf RP, Schreiber NA et al (2018) Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 36(Suppl 6S):abstr 273CrossRefGoogle Scholar
  36. 36.
    Scher H, Lu D, Schreiber NA et al (2016) Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2(11):1441–1449CrossRefGoogle Scholar
  37. 37.
    Scher HI, Fizazi SK, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197CrossRefGoogle Scholar
  38. 38.
    ClinicalTrials.gov (acedido em 25/09/2015). A safety and efficacy study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer (PREVAIL)
  39. 39.
    Armstrong AJ, Garrett-Mayer ES, Yang YC et al (2007) A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13(21):6396–6403CrossRefGoogle Scholar
  40. 40.
    Loriot Y, Massard C, Albiges L et al (2012) Personalizing treatment in patients with castrate-resistant prostate cancer: a study of predictive factors for secondary endocrine therapies activity. J Clin Oncol 30(Suppl 5):abstr 213CrossRefGoogle Scholar
  41. 41.
    Angelergues A, Maillet D, Fléchon A et al (2014) Duration of response to androgen-deprivation therapy and efficacy of secondary hormone therapy, docetaxel, and cabazitaxel in metastatic castration-resistant prostate cancer. J Clin Oncol 32(Suppl 4):abstr 282CrossRefGoogle Scholar
  42. 42.
    Sweeney C, Chen YH, Carducci MA et al (2014) Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial. J Clin Oncol 32(5 suppl):abstr LBA2CrossRefGoogle Scholar
  43. 43.
    ClinicalTrials.gov (acedido em 25/09/2015) STAMPEDE: systemic therapy in advancing or metastatic prostate cancer: evaluation of drug efficacy: a multi-stage multi-arm randomised controlled trial
  44. 44.
    Fizazi K, Scher HI, Molina A et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo controlled phase 3 study. Lancet Oncol 13:983–992CrossRefGoogle Scholar
  45. 45.
    Robinson D, Van Allen EM, Wu YM et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161:1215–1228CrossRefGoogle Scholar
  46. 46.
    Mateo J, Carreira S, Sandhu S et al (2015) DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373:1697–1708CrossRefGoogle Scholar
  47. 47.
    Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B (2016) Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. Eur Urol 69:992–995CrossRefGoogle Scholar
  48. 48.
    de Bono JS, De Giorgi U, Massard C et al (2016) PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate. Ann Oncol 27(Suppl 6):7180 AbstractGoogle Scholar
  49. 49.
    Ipatasertib plus abiraterone plus prednisone/prednisolone, relative to placebo plus abiraterone plus prednisone/prednisolone in adult male patients with metastatic castrate-resistant prostate cancer (IPATential150). https://clinicaltrials.gov/ct2/show/NCT03072238
  50. 50.
    Pritchard CC, Morrissey C, Kumar A et al (2014) Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun 5:4988CrossRefGoogle Scholar
  51. 51.
    FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. Food and Drug Administration, Silver Spring, MD, 30 May 2017. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm560040.htm
  52. 52.
    Graff JN, Alumkal JJ, Drake CG et al (2016) Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 7:52810–52817PubMedPubMedCentralGoogle Scholar
  53. 53.
    Rahbar K, Ahmadzadehfar H, Kratochwil C et al (2017) German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 58:85–90CrossRefGoogle Scholar
  54. 54.
    Kratochwil C, Bruchertseifer F, Rathke H et al (2017) Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med 58:1624–1631CrossRefGoogle Scholar
  55. 55.
    Hernandez-Hoyos G, Sewell T, Bader R et al (2016) MOR209/ES414, a novel bispecific antibody targeting PSMA for the treatment of metastatic castration-resistant prostate cancer. Mol Cancer Ther 9:2155–2165CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • André Mansinho
    • 1
  • Daniela Macedo
    • 1
  • Isabel Fernandes
    • 2
    • 3
  • Luís Costa
    • 2
    • 3
  1. 1.Oncology Department, Hospital de Santa MariaCentro Hospitalar Lisboa NorteLisbonPortugal
  2. 2.Department of Oncology, Hospital de Santa MariaCentro Hospitalar Lisboa NorteLisbonPortugal
  3. 3.Oncology Division, Faculdade de Medicina de LisboaInstituto de Medicina MolecularLisbonPortugal

Personalised recommendations